Advances in induction of ovulation

Area of Science:

• Reproductive Endocrinology
• Infertility Treatment

Background:

• Polycystic ovary syndrome (PCOS) and hypogonadotropic hypogonadism are common causes of anovulatory infertility.
• Clomiphene citrate is a first-line treatment, but resistance necessitates alternative strategies.
• Minimizing multiple folliculogenesis is crucial to avoid complications associated with ovulation induction.

Purpose of the Study:

• To review current and emerging treatment options for clomiphene-resistant PCOS and hypogonadotropic hypogonadism.
• To highlight advancements in ovulation induction therapies.
• To discuss the role of new pharmacological agents in managing anovulation.

Main Methods:

• Literature review of recent studies on ovulation induction.
• Analysis of clinical applications of recombinant human follicle-stimulating hormone (FSH).
• Evaluation of the potential role of long-acting opiate agonists in hypothalamic anovulation.

Main Results:

• Low-dose ovulation induction regimens are increasingly used, especially for PCOS, to mitigate risks of multiple pregnancies.
• Recombinant human FSH (rhFSH) has emerged as a viable clinical option for ovulation induction.
• Long-acting opiate agonists show promise in managing hypothalamic anovulation.

Conclusions:

• Effective management of clomiphene-resistant anovulation requires tailored approaches.
• Advancements in reproductive technologies, including rhFSH, offer new hope for infertile women.
• Further research into novel agents like opiate agonists may expand treatment paradigms for anovulatory disorders.